You just read:

ThromboGenics and BioInvent Announce the Start of New Study of Novel Antibody Anti-Cancer Agent TB-403 (Anti-PlGF) by Partner Roche

News provided by

ThromboGenics NV

16 May, 2011, 06:30 BST